Abstract

Major depressive disorder (MDD) contributes significantly to morbidity, disability, and decreased quality of life, despite the expansion of treatment options. This, in part, is caused by a lack of valid, applicable, and reliable biomarkers to predict the risk, treatment response, and prognosis of depression. In recent years, the anterior cingulate cortex, in particular pars subgenual (sgACC), has received much attention due to its potential utilization as a neural endophenotype for depression. This essay will discuss the functional activity of sgACC, mostly by functional magnetic resonance imaging, in relation to predicting risk for developing depression, predicting patient response-to-treatment, and eventually, to create a platform for personalized psychiatric approach to each patient. The caveats and conditions need to be met will also be discussed, in order to firmly establish sgACC activity as a valid biomarker for depression.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call